DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced its participation in three investor conferences in March 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the company’s participation are as follows:
-
33rd Annual Roth Conference
Details: DiaMedica Therapeutics management will deliver a fireside chat and participate in 1-on-1 meetings
Company conference participation date: March 15th, 2021
-
Oppenheimer’s 31st Annual Healthcare Conference
Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
Company conference participation date: March 16th, 2021
-
Maxim’s Emerging Growth Conference
Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
Company conference participation date: March 17th, 2021
For more information or to schedule a one-on-one meeting with management, please contact your conference representative.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, please visit www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005912/en/